Company Overview and News

0
Critical Control Announces Its Annual General Meeting Voting Results

2018-06-19 globenewswire
CALGARY, Alberta, June 19, 2018 (GLOBE NEWSWIRE) -- Critical Control Energy Services Corp. (“Critical Control” or the “Corporation”) (TSX:CCZ) announces that all the motions put forth at its annual general meeting held in Calgary on June 19, 2018 were approved by the shareholders. The detailed results of the voting are as follows:
CCZ CCZFF

0
Critical Control Declares Dividend

2018-06-11 globenewswire
CALGARY, Alberta, June 11, 2018 (GLOBE NEWSWIRE) -- Critical Control Energy Services Corp. (“Critical Control” or the “Corporation”) (TSX:CCZ) (TSX:CCZ.PR.A) announces that the directors of the Corporation declared a quarterly cash dividend on its series A preferred shares of $0.04 per share, payable on or about June 30, 2018 to shareholders of record at the close of business on June 15, 2018. This dividend represents a cash dividend of $0.
CCZ CCZFF

0
Early Warning Report

2018-06-06 globenewswire
CALGARY, Alberta, June 06, 2018 (GLOBE NEWSWIRE) -- Critical Control Energy Services Corp. (TSX:CCZ) ("Critical Control") announces that Mr. Alykhan Mamdani, President and CEO of Critical Control has purchased 2,827,504 common shares of Critical Control at a purchase price of $0.19 per share in a private transaction.
CCZ CCZFF

0
Critical Control Announces First Quarter 2018 Financial Results

2018-05-09 globenewswire
CALGARY, Alberta, May 08, 2018 (GLOBE NEWSWIRE) -- Critical Control Energy Services Corp. (TSX:CCZ) today reported its financial results for the three months ended March 31, 2018.
CCZ CCZFF

0
Critical Control Energy Services Corp. - Early Warning Report

2018-04-13 globenewswire
CALGARY, Alberta, April 13, 2018 (GLOBE NEWSWIRE) -- Alykhan Mamdani, President and CEO of Critical Control Energy Services Corp. (“Critical Control”) (TSX:CCZ), has filed an Early Warning Report in accordance with National Instrument 62-103 The Early Warning System and Related Take Over Bids and Insider Reporting Issues, in connection with his acquisition of 33,761 common shares of Critical Control under Critical Control’s employee share purchase plan (the “ESPP Acquisition”).
CCZ CCZFF

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

2018-06-22 - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2018-06-22 - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

Silicon Investor Message Boards

This table lists all message boards related to TSX:CCZ / Criticalcontrol Solution on message board site Silicon Investor.

CCZ - COMMERCIAL CONSOLIDATORS - Company Website http://comm CASTELLO CASINO CORP. (CCCZ/CSTC)